rAAV-related therapy fully rescues myonuclear and myofilament function in X-linked myotubular myopathy

Archive ouverte

Ross, Jacob | Tasfaout, Hichem | Levy, Yotam | Morgan, Jennifer | Cowling, Belinda | Laporte, Jocelyn | Zanoteli, Edmar | Romero, Norma | Lowe, Dawn | Jungbluth, Heinz | Lawlor, Michael | Mack, David | Ochala, Julien

Edité par CCSD ; BioMed Central part of Springer Science -

International audience. X-linked myotubular myopathy (XLMTM) is a life-threatening skeletal muscle disease caused by mutations in the MTM1 gene. XLMTM fibres display a population of nuclei mispositioned in the centre. In the present study, we aimed to explore whether positioning and overall distribution of nuclei affects cellular organization and contractile function, thereby contributing to muscle weakness in this disease. We also assessed whether gene therapy alters nuclear arrangement and function. We used tissue from human patients and animal models, including XLMTM dogs that had received increasing doses of recombinant AAV8 vector restoring MTM1 expression (rAAV8-cMTM1). We then used single isolated muscle fibres to analyze nuclear organization and contractile function. In addition to the expected mislocalization of nuclei in the centre of muscle fibres, a novel form of nuclear mispositioning was observed: irregular spacing between those located at the fibre periphery, and an overall increased number of nuclei, leading to dramatically smaller and inconsistent myonuclear domains. Nuclear mislocalization was associated with decreases in global nuclear synthetic activity, contractile protein content and intrinsic myofilament force production. A contractile deficit originating at the myofilaments, rather than mechanical interference by centrally positioned nuclei, was supported by experiments in regenerated mouse muscle. Systemic administration of rAAV8-cMTM1 at doses higher than 2.5 × 1013 vg kg-1 allowed a full rescue of all these cellular defects in XLMTM dogs. Altogether, these findings identify previously unrecognized pathological mechanisms in human and animal XLMTM, associated with myonuclear defects and contractile filament function. These defects can be reversed by gene therapy restoring MTM1 expression in dogs with XLMTM.

Suggestions

Du même auteur

Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice

Archive ouverte | Tasfaout, Hichem | CCSD

Centronuclear myopathies (CNM) are non-dystrophic muscle diseases for which no effective therapy is currently available. The most severe form, X-linked CNM, is caused by myotubularin 1 (MTM1) loss-of-function mutations, while the ...

Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation

Archive ouverte | Cowling, Belinda | CCSD

International audience. Regulation of skeletal muscle development and organization is a complex process that is not fully understood. Here, we focused on amphiphysin 2 (BIN1, also known as bridging integrator-1) and...

Physiological impact and disease reversion for the severe form of centronuclear myopathy linked to dynamin Graphical abstract

Archive ouverte | Muñoz, Xènia Massana | CCSD

International audience. Classical dynamins are large GTPases regulating membrane and cytoskeleton dynamics, and they are linked to different pathological conditions ranging from neuromuscular diseases to encephalopa...

Chargement des enrichissements...